Patrícia Gomes

Patrícia Gomes

Auto-generated profile, based on publicly available information

Patrícia Gomes

Universidade Franciscana

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2021 in Colloids and Surfaces B: Biointerfaces
Verified
Journal Article
Closed access
ADAna Júlia F. Dalcin
Ana Júlia F. Dalcin
IRIsabel Roggia
Isabel Roggia
SFSabrina Felin
Sabrina Felin
Bruno Stefanello VizzottoBruno Stefanello Vizzotto
Bruno Stefanello Vizzotto
MAMontse Mitjans Arnal
Montse Mitjans Arnal
PGPatrícia Gomes
Patrícia Gomes

1 March 2020 in Colloids and Surfaces B: Biointerfaces
Verified
Journal Article
Closed access
IRIsabel Roggia
Isabel Roggia
ADAna Júlia F. Dalcin
Ana Júlia F. Dalcin
AOAline Ferreira Ourique
Aline Ferreira Ourique
ICIvana Beatrice Beatrice Mânica Mânica Da Cruz
Ivana Beatrice Beatrice Mânica Mânica Da Cruz
EREuler Esteves Ribeiro
Euler Esteves Ribeiro
PGPatrícia Gomes
Patrícia Gomes

12 May 2023 in Cosmetics
Verified
Journal Article
Open access
PDF file
IRIsabel Roggia
Isabel Roggia
PGPatrícia Gomes
Patrícia Gomes
ADAna Julia Figueiró Dalcin
Ana Julia Figueiró Dalcin
AOAline Ferreira Ourique
Aline Ferreira Ourique
ICIvana Beatrice Beatrice Mânica Mânica Da Cruz
Ivana Beatrice Beatrice Mânica Mânica Da Cruz
Maria Pilar VinardellMaria Pilar Vinardell
Maria Pilar Vinardell
The objective of this study was to analyze the in vitro stability and toxicity of liposomes containing guarana in skin cell lines. The liposomes were produced by the reverse phase evaporation method containing 1 mg/mL guarana. The stability of the liposomes was evaluated by physical-chemical parameters for up to 90 days using three different storage conditions. The cytotoxicity of guarana (GL), liposomes (B-Lip), and guarana-loaded liposomes (G-Lip) was evaluated on spontaneously immortalized human keratinocyte cell lines (HaCaT), murine Swiss albino fibroblasts (3T3), and human fibroblasts (1BR.3.G). The evaluation was performed using cellular viability analysis. The techniques used were 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) and neutral red capturing (NRU), and the analyses were conducted after 24, 48, and 72 h of exposure of these cells to the different treatments. The G-Lip exhibited physical-chemical stability for 60 days when the samples were stored in a refrigerator. The GL, B-Lip, and G-Lip demonstrated low cytotoxicity in the three different cell cultures tested since a small reduction in cell viability was only observed at the highest concentrations. In addition, greater cell damage was observed for B-Lip; however, guarana protected the cells from this damage. Thus, G-Lip structures can be considered promising systems for topical applications.

19 May 2019 in Journal of Microencapsulation
Verified
Journal Article
Closed access
RLRicardo Lorenzoni
Ricardo Lorenzoni
LCLeticia Malgarim Cordenonsi
Leticia Malgarim Cordenonsi
SDSamuel Davies
Samuel Davies
MAMichelli Barcelos Antonow
Michelli Barcelos Antonow
ADAline Scheinder Medina Diedrich
Aline Scheinder Medina Diedrich
RRRenata Platcheck Raffin
Renata Platcheck Raffin
Aims: Lipid-core nanocapsules (LNCs) loaded with simvastatin (SV, SV-LNC) or lovastatin (LV, LV-LNC) were formulated for pulmonary administration. Methods: The LNC suspensions were characterized physicochemically, their stability was evaluated, and drug delivery by the pulmonary route was tested in vitro. Results: The loaded LNCs had a particle size close to 200 nm, a low polydispersity index, and a zeta potential around −20 mV. The encapsulation efficiency was high for SV (99.21 ± 0.7%) but low for LV (20.34 ± 1.2%). SV release from nanocapsules was slower than it was from SV in solution, with a monoexponential release profile, and the drug emitted and aerosol output rate was higher for SV-LNCs (1.58 µg/s) than for SV in suspension (0.54 µg/s). Conclusions: SV-LNCs had a median aerodynamic diameter of 3.51 µm and a highly respirable fraction (61.9%), indicating that nanoparticles are a suitable system for efficient delivery of simvastatin to the lung.

10 June 2022 in Disciplinarum Scientia - Ciências Naturais e Tecnológicas
Verified
Journal Article
Open access
PDF file
ASAndré Flores dos Santos
André Flores dos Santos
MMMirkos Ortiz Martins
Mirkos Ortiz Martins
GMGiane Engel Montagner
Giane Engel Montagner
JSJúlia Vaz Schultz
Júlia Vaz Schultz
PGPatrícia Gomes
Patrícia Gomes
SFSolange Binotto Fagan
Solange Binotto Fagan
In March 2020, it was declared a coronavirus (COVID-19) pandemic disease state by the World Health Organization, which represents a public health concern. Several antiviral and non-antiviral drugs are currently being tested against the COVID-19 disease, some of which have already been approved by health regulatory bodies in some countries. In this study, the objective was to identify the best drugs that are being used to fight the virus through computer simulations in addition to predicting toxicity and antiviral activity. Thus, molecular docking of the compounds arbidol, baricitinib, camostat mesylate, favipiravir, heparin, hydroxychloroquine, molnupiravir, paxlovid, and remdesivir was performed to discover the best points of interaction in the cellular organelles involved in the process of cellular infection by SARS-CoV- 2 and the prediction of toxicology and antiviral activity of the compounds was performed by online computer simulation programs: pkCSM, ProTox-II, GUSAR, ROSC-Pred, and AntiVir-Pred. The best results highlight the drugs heparin as a good protein S blocker, paxlovid as a protease inhibitor, arbidol as a viral entry blocker, baricitinib as an RNA replication inhibitor, and membrane fusion inhibitor. All compounds showed a low risk of toxicity, as most showed antiviral activity. Thus, all compounds, except favipiravir, demonstrated some type of interaction with target cell organelles, but more studies are needed, such as in vitro and in vivo, to obtain reliable results for treatment with small doses of the drug, since the prediction showed small rates of the toxicity, mainly hepatic.

29 December 2021 in Disciplinarum Scientia - Ciências Naturais e Tecnológicas
Verified
Journal Article
Open access
PDF file
ASAndré Flores dos Santos
André Flores dos Santos
AFAlessandra Soares Ayres Fraga
Alessandra Soares Ayres Fraga
PGPatrícia Gomes
Patrícia Gomes
SFSolange Binotto Fagan
Solange Binotto Fagan
In March 2020, it was declared a state of pandemic coronavirus disease (COVID-19) by the World Health Organization, which represents a public health concern. Some vaccines were created to fight the COVID-19 disease and use nanotechnology in their composition. Vaccines approved in clinical trials that are currently available for the population using nanotechnology are BNT162b2 (Pfizer, 95% effective), and mRNA-1273 (Modern, 94, 5% effectiveness). These vaccines use lipid nanoparticles, loaded with RNA (mRNA) to fight SARS-Cov-2. Nanotechnology can have several advantages in creating vaccines, for example, antigen protection by premature degradation to increase the immune response, control release kinetics, provide site-specific antigens, and facilitate intracellular absorption. This review article seeks to present applications of nanostructures in the production of vaccines against COVID-19 that are in the clinical testing phase and also those that have already been approved.